A prospective study in heart and lung transplant recipients correlating persistent Epstein-Barr virus infection with clinical events

Transplantation

Volumn 64, Issue 7, 1997, Pages 1028-1034

  Haque, Tanzina ^a   Thomas, J Alero ^b   Parratt, Rachel ^c   Hunt, Beverley J ^c   Yacoub, Magdi H ^c   Crawford, Dorothy H ^a  

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

^b LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^c HAREFIELD HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; ANTIVIRUS AGENT; AZATHIOPRINE; CYCLOSPORIN A; IMMUNOSUPPRESSIVE AGENT; METHYLPREDNISOLONE; PREDNISOLONE; STEROID;

ADOLESCENT; ADULT; ARTICLE; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; EPSTEIN BARR VIRUS; FEMALE; GRAFT REJECTION; HEART TRANSPLANTATION; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LUNG TRANSPLANTATION; MALE; ORGAN TRANSPLANTATION; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; TREATMENT OUTCOME; VIRUS DETECTION; VIRUS INFECTION;

ADOLESCENT; ADULT; CHILD; CHILD, PRESCHOOL; CYTOTOXICITY, IMMUNOLOGIC; DNA, VIRAL; FEMALE; FOLLOW-UP STUDIES; GRAFT REJECTION; HEART TRANSPLANTATION; HEART-LUNG TRANSPLANTATION; HERPESVIRIDAE INFECTIONS; HERPESVIRUS 4, HUMAN; HUMANS; IMMUNOSUPPRESSION; INFANT; KIDNEY TRANSPLANTATION; LIVER TRANSPLANTATION; LUNG TRANSPLANTATION; MALE; MIDDLE AGED; POSTOPERATIVE COMPLICATIONS; PROSPECTIVE STUDIES; REFERENCE VALUES; REGRESSION ANALYSIS; T-LYMPHOCYTES, CYTOTOXIC; TUMOR VIRUS INFECTIONS;

EID: 0030864937     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007890-199710150-00015     Document Type: Article

References (40)

1. Epstein MA, Achong BG, Barr YM. Virus particles in cultured lymphoblasts from Burkitt lymphoma. Lancet 1964; 1: 702.
2. Klein G. The relationship of the virus to nasopharyngeal carcinoma. In Epstein MA, Achong BG, eds. The Epstein-Barr virus. Berlin: Springer-Verlag, 1979: 339
3. Weiss LM, Movahed LA, Warnke RA, Sklar J. Detection of Epstein-Barr viral genomes in Reed-Sternberg cells of Hodgkin's disease. N Engl J Med 1989; 320: 502.
4. Crawford DH, Epstein MA, Bornkamn GW, Achong BG, Finerty S, Thompson JL. Epstein-Barr virus nuclear antigen positive lymphoma after cyclosporine A treatment in a patient with renal allograft. Lancet 1980; 1: 1355.
5. Zeigler JI, Beckstead JA, Volberding PA. Non-Hodgkin's lymphoma in 90 homosexual men: relation to generalised lymph-adenopathy and the acquired immunodeficiency syndrome. N Engl J Med 1984; 311: 565.
6. Henle G and Henle W. Seroepidemiology of the virus. In: Epstein MA, Achong BG, eds. The Epstein-Barr virus. Berlin: Springer-Verlag, 1979: 297.
7. Pope JH, Horne MK, Scott W. Transformation of human foetal leucocytes in vitro by infiltrates of a human leukaemia cell line containing herpes-like virus. Int J Cancer 1968; 3: 857.
8. Miyashita EM, Yang B, Lam KMC, Crawford DH, Thorley-Lawson DA. A novel form of Epstein-Barr virus latency in normal B cells. Cell 1995; 80: 593.
9. Sixbey JW, Nedrud JG, Raab-Traub N, Hanes RA, Pagano JS. Epstein-Barr virus replication in oropharyngeal epithelial cells. N Engl J Med 1984; 310: 1225.
10. Moss DJ, Wallace LE, Rickinson AB, Epstein MA. Cytotoxic T-cell recognition of Epstein-Barr virus infected B-cells: I. specificity and HLA-restriction of effector cells reactivated in vitro. Eur J Immunol 1989; 11: 686.
11. Wallace CE, Rickinson AB, Rowe M, Epstein MA. Epstein-Barr virus-specific cytotoxic T-cell clones restricted through a single HLA antigen. Nature 1982; 297: 413.
12. Savoie A, Perpete C, Carpentier L, Joncas J, Alfieri C. Direct correlation between the load of Epstein-Barr virus-infected lymphocytes in the peripheral blood of paediatric transplant patients and risk of lymphoproliferative disease. Blood 1994; 9: 2715.
13. Preiksaitis JK, Diaz-Mitoma F, Mirzayans F, Roberts S, Tyrrell DLJ. Quantitative oropharyngeal Epstein-Barr virus shedding in renal and cardiac transplant recipients: relationship to immunosuppressive therapy, serological responses and the risk of post-transplant lymphoproliferative disorder. J Infect Dis 1992; 166: 986.
14. Ho M, Miller G, Wayne A, et al. Epstein-Barr virus infection and DNA hybridisation studies in post-transplant lymphomas and lymphoproliferative lesions: the role of primary infection. J Infect Dis 1985; 152: 876.
15. Thomas JA, Crawford DH, Burke M. Clinicopathological implications of Epstein-Barr virus related B cell lymphoma in immunocompromised patients. J Clin Pathol 1995; 48: 287.
16. Opelz G, Henderson R. Incidence of non-Hodgkin lymphoma in kidney and heart transplant recipients. Lancet 1993; 342: 1514.
17. Randhawa PS, Yousem SA, Paradis IL, Dauber JA, Griffith BP, Locker J. The clinical spectrum, pathology, and clonal analysis of Epstein-Barr virus-associated lymphoproliferative disorders in heart-lung transplant recipients. Am J Clin Pathol 1989; 92: 177.
18. Cox KL, Lawrence-Miyasaki LS, Garcia-Kennedy R, et al. An increased incidence of Epstein-Barr virus infection and lymphoproliferative disorder in young children on FK506 after liver transplantation. Transplantation 1995; 59: 524.
19. Alfrey EJ, Friedman AL, Grossman RA, et al. A recent decrease in the time to development of monomorphous and polymorphous post-transplant lymphoproliferative disorder. Transplantation 1992; 54: 250.
20. Ho M, Jaffe R, Miller G, et al. The frequency of Epstein-Barr virus infection and associated lymphoproliferative disease after transplantation and its manifestations in children. Transplantation 1988; 45: 719.
21. Henle G, Henle W. Immunofluorescence in cells derived from Burkitt's lymphoma. J Bacteriol 1966; 91: 1248.
22. Henle G, Henle W, Klein G. Demonstration of two distinct components in the early antigen complex of Epstein-Barr virus-infected cells. Int J Cancer 1971; 8: 272.
23. Moss DJ, Rickinson AB, Pope JH. Long-term T-cell mediated immunity to Epstein-Barr virus in man: I. complete regression of virus-induced transformation in cultures of seropositive donor leukocytes. Int J Cancer 1978; 24: 662.
24. Boyum A. Separation of leucocytes from blood and bone marrow. Scan J Clin Lab Invest 1968; 21 (suppl 97): 31.
25. Kaplan ME, Clarke C. An improved rosetting assay for detection of human T lymphocytes. J Immunol Methods 1974; 5: 131.
26. Burnette WN. Western blotting: electrophoretic transfer of proteins from dodecyl sulphate polyacrylamide gels to nitrocellulose and radiographic detection with antibody and radioiodinated protein A. Anal Biochem 1981; 112: 195.
27. Sambrook J, Fritsch EF, Maniatis T. Molecular cloning: a laboratory manual, 2nd ed. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory, 1989.
28. Miller G, Shope T, Lisco H, Stitt D, Lipman A. Epstein-Barr virus: transformation cytopathic changes and viral antigens in squirrel monkey and marmoset leukocytes. Proc Natl Acad Sci USA 1972; 69: 383.
29. Klein G, Giovanella B, Westman A, Stehlin JS, Mumford D. An EBV-genome negative cell line established from an American Burkitt's lymphoma: receptor characteristics, EBV infectability and permanent conversion into EBV-positive sublines by in vitro infection. Intervirology 1975; 5: 319.
30. Saiki RK, Scharf S, Faloona F, et al. Enzymatic amplification of β-globin genomic sequences and restriction site analysis for diagnosis of sickle cell anaemia. Science 1985; 230: 1350.
31. Boyle MJ, Sewell WA, Sculley TB, et al. Subtypes of Epstein-Barr virus in human immunodeficiency virus-associated non-Hodgkin's lymphoma. Blood 1991; 78: 3004.
32. Adldinger HK, Delius H, Freese UK, Clarke J, Bornkamm GW. A putative transforming gene of Jijoye virus differs from that of Epstein-Barr virus prototypes. Virology 1985; 141: 221.
33. Haque T, Thomas JA, Falk KI, et al. Transmission of donor Epstein-Barr virus (EBV) in transplanted organs causes lymphoproliferative disease in EBV-seronegative recipients. J Gen Virol 1996; 77: 1169.
34. Yao QY, Rickinson AB, Epstein MA. A re-examination of the Epstein-Barr virus carrier state in healthy seropositive individuals. Int J Cancer 1985; 35: 35.
35. Colby B, Shaw J, Elion G, Pagano J. Effects of acyclovir [9-(2-hydroxyethoxymethyl) guanine] on Epstein-Barr virus DNA replication. J Virol 1980; 34: 560.
36. Yao QY, Ogan P, Rowe M, Wood M, Rickinson AB. Epstein-Barr virus immortalized B-cells persist in the circulation of acyclovir-treated virus carriers. Int J Cancer 1989; 43: 67.
37. Cen H, Breinig MC, Atchison RW, Ho M, McKnight JLC. Epstein-Barr virus transmission via the donor organ in solid organ transplantation: polymerase chain reaction and restriction fragment length polymorphism analysis of IR2, IR3 and IR4. J Virol 1991; 65: 976.
38. Van Gelder T, Kroes LCM, Mulder A, Gratama JW, Weimer W. A living-related kidney donor as the source of a nearly fatal primary Epstein-Barr virus infection following transplantation. Transplantation 1994; 58: 852.
39. Smith JD, Rose ML, Pomerance A, Burke M, Yacoub MH. Reduction of cellular rejection and increase in long-term survival after heart transplantation after HLA-DR matching. Lancet 1995; 346: 1318.
40. Epstein MA, Morgan AJ, Finerty S, Randle BJ, Kirkwood JK. Protection of cottontop tamarins against EB virus-induced malignant lymphoma by a prototype subunit vaccine. Nature 1985; 318: 287.